Desogestrel-Ethinyl Estradiol — Discount Pricing

Other medications in Women's Health

• Dienogest
• Dinoprostone
• Drospirenone-Ethinyl Estradiol
• Elagolix
• Emergency Contraception
• GnRH Agonist
• GnRH Antagonist
• Gonadotropins FSH

What Desogestrel-Ethinyl Estradiol is approved for (FDA label)

Isibloom TM (desogestrel and ethinyl estradiol tablets) are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and the Norplant System depends upon the reliability with which they are used. Correct and consistent use of these methods can result in lower failure rates. In a clinical trial with desogestrel and ethinyl estradiol tablets, 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported.

Source: Read the full FDA label on DailyMed. Label effective date: August 12, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Desogestrel-Ethinyl Estradiol (FDA label)

WARNING: CARDIOVASCULAR RISK ASSOCIATED WITH SMOKING Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, combination oral contraceptives, including desogestrel and ethinyl estradiol tablets, should not be used by women who are over 35 years of age and smoke.

Source: FDA prescribing information (DailyMed). Set ID: 4a8f278f-f505-4537-8deb-74e8927df8c6. SPL document ID: c4f10760-aa41-4132-badd-4dcf0be4b361. Label effective date: August 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Desogestrel-Ethinyl Estradiol (FDA label)

Post Marketing Experience Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 - 1.12 (Figure 2). Three studies compared breast cancer risk between current or recent COC users (<6 months since last use) and never users of COCs (Figure 2). One of these studies reported no association between breast cancer risk and COC use. The other two studies found an increased relative risk of 1.19 - 1.33 with current or recent use.

Source: FDA prescribing information (DailyMed). Set ID: 4a8f278f-f505-4537-8deb-74e8927df8c6. SPL document ID: c4f10760-aa41-4132-badd-4dcf0be4b361. Label effective date: August 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Desogestrel-Ethinyl Estradiol (FDA label)

Isibloom is contraindicated in females who are known to have or develop the following conditions: • Thrombophlebitis or thromboembolic disorders • A past history of deep vein thrombophlebitis or thromboembolic disorders • Known thrombophilic conditions • Cerebral vascular or coronary artery disease (current or history) • Valvular heart disease with complications • Persistent blood pressure values of ≥ 160 mm Hg systolic or ≥ 100 mg Hg diastolic 102 • Diabetes with vascular involvement • Headaches with focal neurological symptoms • Major surgery with prolonged immobilization • Current diagnosis of, or history of, breast cancer, which may be hormone sensitive • Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia • Undiagnosed abnormal genital bleeding • Cholestatic jaundice of pregnancy or jaundice with prior pill use • Acute or chronic hepatocellular disease with abnormal liver function • Hepatic adenomas or carcinomas • Known or suspected pregnancy

Source: FDA prescribing information (DailyMed). Set ID: 4a8f278f-f505-4537-8deb-74e8927df8c6. SPL document ID: c4f10760-aa41-4132-badd-4dcf0be4b361. Label effective date: August 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Desogestrel-Ethinyl Estradiol (FDA label)

Consult the labeling of concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations. Effects of Other Drugs on Combined Hormonal Contraceptives Substances decreasing the plasma concentrations of COCs and potentially diminishing the efficacy of COCs Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the plasma concentrations of COCs and potentially diminish the effectiveness of CHCs or increase breakthrough bleeding. Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. Interactions between hormonal contraceptives and other drugs may lead to breakthrough bleeding and/or contraceptive failure.

Source: FDA prescribing information (DailyMed). Set ID: 4a8f278f-f505-4537-8deb-74e8927df8c6. SPL document ID: c4f10760-aa41-4132-badd-4dcf0be4b361. Label effective date: August 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.